Eli Lilly and Company has unveiled plans to invest over $470 million and create more than 460 new jobs in Durham, NC. The project will bring a new state-of-the-art pharmaceutical manufacturing facility to North Carolina’s Research Triangle Park.
 
This new manufacturing site will be a state-of-the-art facility that produces parenteral (or injectable) products and delivery devices. To operate the site, Lilly will create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations. Lilly currently has seven manufacturing sites located in the U.S. in Indiana, New Jersey and Puerto Rico.
 
“This next-generation manufacturing facility will allow us to expand our capacity to make the Lilly medicines that are helping people with serious illnesses today, and help us prepare for new medicines coming from our robust pipeline in the future,” said David Ricks, chairman and chief executive officer, Lilly. “In the past two years, we have invested billions of capital in new U.S.-based manufacturing because the 2017 tax reform rebalanced the playing field in favor of the American worker. We’re excited to be bringing more of these high-skill, high-wage advanced manufacturing jobs to North Carolina.”